Basic Information
| LncRNA/CircRNA Name | SPRY4-IT1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000281881 |
| Refseq | NR_131221 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | RT-qPCR, Western blot, RNAi |
| Sample | OS cell lines |
| Expression Pattern | up-regulated |
| Function Description | SPRY4-IT1 inhibition increased miR-101 levels, resulting in downregulation of ZEB1/2 expression and thus exerting anti-tumour effects in OS. |
| Pubmed ID | 31746422 |
| Year | 2019 |
| Title | LncRNA SPRY4-IT1 promotes progression of osteosarcoma by regulating ZEB1 and ZEB2 expression through sponging of miR-101 activity |
External Links
| Links for SPRY4-IT1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |